Introduction
Methods
Patients and breast cancer tissues
Parameter | Value (n [%]) |
---|---|
n
| 506 |
Age at diagnosis (years) | |
≤ 50 | 211 (42) |
> 50 | 295 (58) |
Age range (years) | 22–91 |
Tumor size (cm) | |
< 2 | 209 (41) |
≥ 2 | 295 (59) |
Number of positive lymph nodes | |
0 | 276 (57) |
1–3 | 115 (24) |
> 3 | 93 (19) |
Histological grade | |
1 | 93 (17) |
2 | 291 (59) |
3 | 116 (24) |
Adjuvant therapy | |
None | 137 (27) |
Endocrine therapy | 101 (20) |
Chemotherapy | 85 (17) |
Combined | 183 (36) |
Follow up (months) | |
Mean | 91 |
Median | 82 |
Range | 2–249 |
Immunohistochemical analysis for estrogen receptor-α, HER2, p53, and Ki67
Immunohistochemical scoring
Statistical analysis
Results
Relationship between HER2, p53, and Ki67 expression and clinicopathologic factors
HER2 | p53 | Ki67 | ||||
---|---|---|---|---|---|---|
Parameter | Positive/total (n [%]) |
P
| Positive/total (%) |
P
| Positive/total (%) |
P
|
Total | 104/503 (20.1) | 145/500 (29.0) | 268/500 (53.6) | |||
Tumor size (cm) | ||||||
< 2.0 | 30/208 (14.4) | 0.004 | 44/209 (21.1) | 0.0009 | 110/209 (52.6) | NS |
≥ 2.0 | 74/295 (25.1) | 101/291 (34.7) | 158/291 (54.3) | |||
Number of positive lymph nodes | ||||||
0 | 47/276 (17.0) | 0.006 | 72/274 (26.3) | NS | 145/274 (52.9) | NS |
1–3 | 21/115 (18.3) | 32/114 (28.1) | 62/114 (54.4) | |||
> 3 | 30/93 (32.3) | 36/92 (39.1) | 48/92 (52.2) | |||
Histological grade | ||||||
1 | 5/93 (5.4) | < 0.0001 | 7/91 (7.7) | < 0.0001 | 39/91 (42.9) | 0.004 |
2 | 291/58 (19.9) | 82/291 (28.2) | 151/291 (51.9) | |||
3 | 40/116 (34.5) | 55/116 (47.4) | 76/116 (65.5) | |||
Estrogen receptor-α | ||||||
Negative | 70/163 (42.9) | < 0.0001 | 77/162 (47.5) | < 0.0001 | 90/162 (55.6) | NS |
Positive | 34/339 (10.0) | 68/340 (20.0) | 179/340 (52.6) |
Correlation between HER2 over-expression, p53 protein accumulation, and Ki67 expression
p53 | Ki67 | |||
---|---|---|---|---|
Parameter | Positive/total (%) |
P
| Positive/total (%) |
P
|
HER2 | ||||
Negative | 96/398 (24.1) | < 0.0001 | 211/398 (53.0) | NS |
Positive | 49/103 (47.6) | 57/103 (55.3) | ||
p53 | ||||
Negative | 168/357 (47.1) | < 0.0001 | ||
Positive | 101/145 (69.7) |
Disease free and overall survival categorized by HER2, p53, and Ki67 expression
Prognostic analysis of disease free survival
Univariate | Multivariate | ||
---|---|---|---|
Parameter |
P
|
P
| RR (95% CI) |
Tumor size | < 0.0001 | 0.02 | 0.626 (0.418–0.938) |
Number of positive lymph nodes | < 0.0001 | < 0.0001 | 0.227 (0.144–0.359) |
Histological grade | < 0.0001 | 0.09 | 0.712 (0.479–1.057) |
Estrogen receptor-α | 0.03 | 0.42 | 1.176 (0.787–1.756) |
HER2/p53 | < 0.0001 | 0.06 | 0.630 (0.391–1.017) |
Ki67 | 0.001 | 0.003 | 0.589 (0.416–0.833) |
Adjuvant therapy | < 0.0001 | 0.76 | 1.098 (0.606–1.988) |
Prognostic analysis of overall survival
Univariate | Multivariate | ||
---|---|---|---|
Parameter |
P
|
P
| RR (95% CI) |
Tumor size | < 0.0001 | 0.008 | 0.470 (0.273–0.809) |
Number of positive lymph nodes | < 0.0001 | < 0.0001 | 0.275 (0.157–0.482) |
Histological grade | < 0.0001 | 0.09 | 0.665 (0.419–1.056) |
Estrogen receptor-α | 0.002 | 0.16 | 1.389 (0.866–2.229) |
HER2/p53 | < 0.0001 | 0.04 | 0.565 (0.323–0.990) |
Ki67 | 0.28 | ||
Adjuvant therapy | 0.0001 | 0.75 | 0.879 (0.400–1.930) |